NCT00584883已完成1 期
A Phase I Study of ABT 510 and Concurrent Temozolomide and Radiotherapy for Patients With Newly Diagnosed Glioblastoma Multiforme
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- All patients enrolled in this study will be statistically characterized for baseline and disease characteristics using descriptive statistics for continuous measures.
研究概览
简要总结
To determine the maximum tolerated dose of ABT 510 when administered concurrent with radiation therapy for patients with newly diagnosed glioblastoma multiforme.
详细描述
- To describe the toxicity associated with this regimen in adult patients with newly diagnosed glioblastoma multiforme.
- To determine the duration of disease free survival and overall survival associated with this therapy.
- Evaluate thrombospondin 1 (TSP-1) and 2 (TSP-2) in tumor vs. corresponding normal tissue using quantitative real time Polymerase Chain Reaction (Q-RT-PCR).
- Determine the effect of ABT 510 on tumor permeability and tumor blood volume as measured by non-invasive Magnetic Resonance Imaging (MRI).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must be 19 years of age or older.
- •Patients must have histologically proven newly diagnosed glioblastoma multiforme.
- •Patients must have fully recovered from the immediate post-operative period and be maintained on a stable corticosteroid regimen for 5 days prior to entry.
- •Patients must have a Karnofsky performance status > 60% (i.e. the patient must be able to care for himself/herself with occasional help from others).
- •Patients must have adequate hematologic, renal and liver function (i.e. Absolute neutrophil count > 1500/mm3, Platelets > 100,000/mm3, creatinine 1.5 mg/dl .
- •Women of childbearing potential must have a negative pregnancy test.
- •Patients with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods to avoid conception. The effect of the investigational drugs on the developing human fetus is not known, but these drugs are likely to be harmful to the developing fetus or nursing infant. Women of child-bearing potential must agree to use adequate contraception (either surgical sterilization; approved hormonal contraceptives such as birth control pills Depo-Provera, or Lupron Depot; barrier methods such as condom or diaphragm along with spermicide; or an Intrauterine device (IUD)). Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician and study PI immediately.
- •The patient is able to self-administer or has a caregiver who can reliably administer subcutaneous injections.
- •Ability to understand and the willingness to sign a written informed consent document.
排除标准
- •Pregnant or breast feeding.
- •Prior therapy for the brain tumor (except surgery)
- •Prior treatment with antineoplastic agents.
- •Exclude sexually active males and females unwilling to practice contraception during the study.
- •Serious concurrent infections.
- •Clinically significant cardiac disease not well controlled with medication (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias ) or myocardial infarction within the last 12 months.
- •Patients who have had prior cytotoxic chemotherapy prior to radiation therapy.
- •Patients with other serious uncontrolled co-morbid diseases that the investigator feels may comprise the study findings.
- •Patients must be able to learn to self -administer or have another person administer subcutaneous(SQ) injections.
- •Patients who have received any other investigational agents within the 28 days prior to Day 1 of the study.
研究组 & 干预措施
ABT 510
Experimental
The only arm will receive the ABT 510 following standard therapy with radiation and temozolomide chemotherapy concurrent.
干预措施: ABT 510 (Drug)
结局指标
主要结局
All patients enrolled in this study will be statistically characterized for baseline and disease characteristics using descriptive statistics for continuous measures.
时间窗: up to 2 years
The primary outcome for the study was safety and to define the MTD (max tolerated dose). Also, survival was to be measured but the study was not powered to statistically have significance for that measure.
次要结局
未报告次要终点
研究者
Louis Burt Nabors, MD
Professor, Neurology
University of Alabama at Birmingham
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid TumorsSolid TumorsNCT00586092Herbert Hurwitz45
已完成
3 期
A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) AmplificationGlioblastomaGliosarcomaNCT02573324AbbVie691
已完成
2 期
Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed GliomasAnaplastic AstrocytomaGliosarcomaSpinal Cord NeoplasmGlioblastomaCentral Nervous System NeoplasmNCT00100802Children's Oncology Group118
已完成
2 期
Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED)GlioblastomaNCT00684567Merck Sharp & Dohme LLC30
Unknown
1 期
Phase I Study of CCRT as Adjuvant Treatment for Stage II/III Operable Rectal Cancer.Rectal CancerNCT02277158Daping Hospital and the Research Institute of Surgery of the Third Military Medical University18